The Use of Frailty Hazard Models for Unrecognized Heterogeneity That Interacts with Treatment: Considerations of Efficiency and Power
From MaRDI portal
Publication:3078933
DOI10.1111/j.0006-341X.2002.00232.xzbMath1209.62305WikidataQ48664610 ScholiaQ48664610MaRDI QIDQ3078933
Rebecca A. Betensky, J. Gregory Cairncross, David N. Louis, Yi Li
Publication date: 1 March 2011
Published in: Biometrics (Search for Journal in Brave)
Nonparametric hypothesis testing (62G10) Asymptotic properties of nonparametric inference (62G20) Applications of statistics to biology and medical sciences; meta analysis (62P10) Testing in survival analysis and censored data (62N03)
Related Items (7)
Effects of unmeasured heterogeneity in the linear transformation model for censored data ⋮ A Statistical Issue About a Phase III Multi-regional Trial for the Survival Data under Accelerated Failure Time Model with Unrecognized Heterogeneity ⋮ An Approach to Determine Sample Size and to Allocate Sample Size for a Specific Region in a Multiregional Trial for Survival (Time-to-Event) Data under Accelerated Failure Time Model ⋮ Sample Size Determination and Rational Partition for A Multi- Regional Trial for Survival (Time-To-Event) Data with Unrecognized Heterogeneity that Interacts with Treatment ⋮ A Design For Survival Studies: A Multi-regional Trial With Unrecognized Heterogeneity ⋮ The issue about sample size for survival analysis considering the interaction of unrecognized heterogeneity and treatment ⋮ An issue about the efficacy for the time-to-event outcome based on accelerated failure time model with interaction of unrecognized heterogeneity and main effect
Cites Work
This page was built for publication: The Use of Frailty Hazard Models for Unrecognized Heterogeneity That Interacts with Treatment: Considerations of Efficiency and Power
